Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057147 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
A Phase 2 study, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT01057147 is a Phase 2 study that has completed, run by Kubota Vision. The registered enrollment target is 116 participants.
The verdict
NCT01057147, a Phase 2 study, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
Interventions
- DRUG rebamipide 2% ophthalmic suspension
- DRUG placebo eye drops
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057147
The ClinicalTrials.gov registry entry for NCT01057147 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kubota Vision, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rebamipide 2% ophthalmic suspension is the first listed.
NCT01057147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01057147 about?
NCT01057147 is a clinical study titled "Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea". The purpose of this study is to evaluate the safety and efficacy of 2% rebamipide compared to placebo in clearing of fluorescein staining of the central cornea in subjects with dry eye disease.
What is the current status of trial NCT01057147?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2010-02. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01057147?
The interventions under investigation include: rebamipide 2% ophthalmic suspension (DRUG), placebo eye drops (DRUG).
Who is sponsoring clinical trial NCT01057147?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.